source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…Endpoints · 3mo ago↗ source
- Biotech layoffs are easing, but is the worst over?BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.BioPharma Dive · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and morePeople on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipatedSTAT · 3mo ago↗ source